Low-dose nivolumab for adults with HIV on stable therapy
Treatments studied
Part of Infections clinical trials.
This trial tests whether a low dose of nivolumab can safely affect the immune system in adults living with HIV who are already on stable HIV treatment. You may benefit by helping researchers understand a new approach, but the main goal is to check safety and early effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have documented HIV-1 infection.
- Your HIV viral load was previously above 400 copies/mL before starting ART, and now it is below 50 copies/mL at screening for over 2 years.
- You must be taking combination HIV treatment (ART) for at least 2 years, and you must be on the same ART regimen for at least 4 weeks before screening.
- Your CD4 count is above 500 cells per microliter at screening, and you must weigh at least 50 kg.
- You must be able and willing to give informed consent and keep your ART the same during the study (no planned ART changes).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
This trial tests a lower dose of nivolumab (an immunotherapy drug) given less frequently to treat cancers that have spread or cannot be surgically removed. The goal is to see if this approach works well while reducing side effects compared to standard dosing.
This study tests whether giving a small protein called IL-15 can help your immune system keep HIV under control after pausing your daily HIV medications. You will stop your meds for a short time under careful monitoring, and the hope is that your body might learn to fight HIV without daily pills.
This trial tests a lower dose of the immunotherapy drug nivolumab (Opdivo) combined with standard chemotherapy before surgery for patients with early-stage non-small cell lung cancer (NSCLC). The goal is to see if this combination shrinks the tumor and improves outcomes with fewer side effects.
This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.
This study tests a new injectable drug (VH4011499) for safety and how the body processes it. It's for healthy adults without HIV, and participants will get either the study drug or a placebo (an inactive shot).
Hear when a new HIV I Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.